• 1. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 2. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 3. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312
• 4. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 5. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053

Research Brief on 2,3,3a,4,5,6,7,7a-Octahydro-1H-Indole-2-Carboxylic Acid (CAS: 82717-40-6)

2,3,3a,4,5,6,7,7a-Octahydro-1H-indole-2-carboxylic acid (CAS: 82717-40-6) is a bicyclic amino acid derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural features and potential therapeutic applications. This compound serves as a versatile scaffold for the development of novel bioactive molecules, particularly in the areas of central nervous system (CNS) disorders, pain management, and metabolic diseases. Recent studies have explored its role as a precursor for the synthesis of pharmacologically active compounds, including GABA receptor modulators and enzyme inhibitors.

The structural complexity of 2,3,3a,4,5,6,7,7a-octahydro-1H-indole-2-carboxylic acid, characterized by its fused bicyclic ring system and carboxylic acid functionality, makes it an attractive building block for drug discovery. Researchers have leveraged its conformational rigidity to design compounds with enhanced binding affinity and selectivity for target proteins. For instance, derivatives of this compound have shown promising activity as inhibitors of prolyl oligopeptidase (POP), an enzyme implicated in neurodegenerative diseases such as Alzheimer's and Parkinson's.

Recent advancements in synthetic methodologies have enabled more efficient and scalable routes to produce 2,3,3a,4,5,6,7,7a-octahydro-1H-indole-2-carboxylic acid and its derivatives. A study published in the Journal of Medicinal Chemistry (2023) demonstrated a novel asymmetric synthesis approach that significantly improved the yield and enantiomeric purity of the compound. This breakthrough has facilitated further exploration of its pharmacological properties and the development of analogs with optimized pharmacokinetic profiles.

In addition to its applications in CNS drug discovery, 2,3,3a,4,5,6,7,7a-octahydro-1H-indole-2-carboxylic acid has been investigated for its potential in treating metabolic disorders. A 2024 study in Nature Chemical Biology revealed that certain derivatives of this compound act as allosteric modulators of G-protein-coupled receptors (GPCRs) involved in glucose homeostasis. These findings open new avenues for the development of antidiabetic agents with improved safety and efficacy profiles.

The compound's mechanism of action and structure-activity relationships (SAR) have been extensively studied using computational and experimental approaches. Molecular docking and dynamics simulations have provided insights into its binding modes with various biological targets, guiding the rational design of next-generation therapeutics. Furthermore, in vitro and in vivo studies have validated its therapeutic potential, with several derivatives advancing to preclinical development stages.

Despite these promising developments, challenges remain in optimizing the bioavailability and metabolic stability of 2,3,3a,4,5,6,7,7a-octahydro-1H-indole-2-carboxylic acid-based compounds. Researchers are actively exploring prodrug strategies and formulation technologies to address these limitations. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the translation of these discoveries into clinical applications.

In conclusion, 2,3,3a,4,5,6,7,7a-octahydro-1H-indole-2-carboxylic acid (CAS: 82717-40-6) represents a valuable scaffold in medicinal chemistry with diverse therapeutic applications. Ongoing research continues to uncover its potential, driven by advances in synthetic chemistry, computational modeling, and biological evaluation. The compound's unique structural features and pharmacological properties position it as a key player in the development of innovative treatments for complex diseases.

• 80828-13-3((2R,3aR,7aR)-rel-OctahydroIndole-2-carboxylic Acid)
• 80875-98-5((2S,3AS,7aS)-Octahydroindole-2-carboxylic acid)
• 108507-42-2((2R,3aR,7aR)-octahydro-1H-indole-2-carboxylic acid)
• 145438-95-5((2R,3aR,7aS)-Octahydro-1H-indole-2-carboxylic Acid)
• 130092-20-5(D-Proline,4-cyclohexyl-, (4R)-rel- (9CI))
• 145513-93-5((2S,3aS,7aR)-Octahydro-1H-indole-2-carboxylic Acid)
• 103201-78-1((2S,4S)-4-cyclohexylpyrrolidine-2-carboxylic acid)
• 9002-01-1(Streptokinase)
• 145438-94-4((2S,3aR,7aS)-Octahydroindole-2-carboxylic Acid (~90%, contains cis))
• 145513-90-2((2S,3aR,7aR)-octahydro-1H-indole-2-carboxylic acid)